Terms: = Prostate cancer AND SSX1, MGC5162, 6756, ENSG00000126752, RP11-552E4_1, SSRC, MGC150425, Q16384 AND Clinical Outcome
488 results:
1. Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence.
Tamburo M; Buffettino E; Pepe P; Marletta G; Pepe L; Cosentino S; Ippolito M; Pennisi M; Marletta F
Anticancer Res; 2024 May; 44(5):2205-2210. PubMed ID: 38677723
[TBL] [Abstract] [Full Text] [Related]
2. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
3. Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant prostate cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
van der Zande K; Tutuhatunewa-Louhanepessy RD; Hamberg P; Ras S; de Feijter JM; Dezentjé VO; Broeks A; Cornelissen S; Beeker A; van der Noort V; Zwart W; Bergman AM
Clin Genitourin Cancer; 2024 Apr; 22(2):445-453.e1. PubMed ID: 38246830
[TBL] [Abstract] [Full Text] [Related]
4. Single-cell analysis extracted CAFs-related genes to established online app to predict clinical outcome and radiotherapy prognosis of prostate cancer.
Lai C; Wu Z; Li Z; Huang X; Hu Z; Yu H; Yuan Z; Shi J; Hu J; Mulati Y; Liu C; Xu K
Clin Transl Oncol; 2024 May; 26(5):1240-1255. PubMed ID: 38070051
[TBL] [Abstract] [Full Text] [Related]
5. Early response monitoring during [
Neubauer MC; Nicolas GP; Bauman A; Fani M; Nitzsche E; Afshar-Oromieh A; Forrer F; Rentsch C; Stenner F; Templeton A; Schäfer N; Wild D; Chirindel A;
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1185-1193. PubMed ID: 38038755
[TBL] [Abstract] [Full Text] [Related]
6. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
7. A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide.
Buck SAJ; Meertens M; van Ooijen FMF; Oomen-de Hoop E; de Jonge E; Coenen MJH; Bergman AM; Koolen SLW; de Wit R; Huitema ADR; van Schaik RHN; Mathijssen RHJ
Biomed Pharmacother; 2023 Dec; 169():115890. PubMed ID: 37988848
[TBL] [Abstract] [Full Text] [Related]
8. Whole exome germline sequencing in early-onset prostate cancer patients: Genomic findings and clinical outcomes.
Siegelmann-Danieli N; Neiman V; Bareket-Samish A; Berger R; Peretz A; Alapi H; Tsur E; Patalon T; Beller D; Rimler G; Chodick G; Shohat M
Prostate; 2024 Jan; 84(1):39-46. PubMed ID: 37842866
[TBL] [Abstract] [Full Text] [Related]
9. Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced prostate cancer.
Neeb A; Figueiredo I; Gurel B; Nava Rodrigues D; Rekowski J; Riisnaes R; Ferreira A; Miranda S; Crespo M; Westaby D; de Los Dolores Fenor de La Maza M; Guo C; Carmichael J; Grochot R; Tunariu N; Cato ACB; Plymate SR; de Bono JS; Sharp A
Lab Invest; 2023 Nov; 103(11):100245. PubMed ID: 37652207
[TBL] [Abstract] [Full Text] [Related]
10. Early biochemical and radiographic response after one cycle of [
Cytawa W; Hendel R; Tomasik B; Weinzierl FX; Bley T; Jassem J; Schirbel A; Buck AK; Bundschuh RA; Hartrampf PE; Werner RA; Lapa C
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3765-3776. PubMed ID: 37474735
[TBL] [Abstract] [Full Text] [Related]
11. Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 prostate cancer Subtypes.
Chappidi MR; Sjöström M; Greenland NY; Cowan JE; Baskin AS; Shee K; Simko JP; Chan E; Stohr BA; Washington SL; Nguyen HG; Quigley DA; Davicioni E; Feng FY; Carroll PR; Cooperberg MR
Eur Urol Oncol; 2024 Apr; 7(2):222-230. PubMed ID: 37474400
[TBL] [Abstract] [Full Text] [Related]
12. Pro-tumorigenic role of lnc-ZNF30-3 as a sponge counteracting miR-145-5p in prostate cancer.
Le Hars M; Castro-Vega LJ; Rajabi F; Tabatadze D; Romero M; Pinskaya M; Groisman I
Biol Direct; 2023 Jul; 18(1):38. PubMed ID: 37434219
[TBL] [Abstract] [Full Text] [Related]
13. ASCL1-mediated ferroptosis resistance enhances the progress of castration-resistant prostate cancer to neurosecretory prostate cancer.
Nie J; Zhang P; Liang C; Yu Y; Wang X
Free Radic Biol Med; 2023 Aug; 205():318-331. PubMed ID: 37355053
[TBL] [Abstract] [Full Text] [Related]
14. PSMA-heterogeneity in metastatic castration-resistant prostate cancer: Circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy.
Derlin T; Riethdorf S; Schumacher U; Lafos M; Peine S; Coith C; Ross TL; Pantel K; Bengel FM
Prostate; 2023 Aug; 83(11):1076-1088. PubMed ID: 37147881
[TBL] [Abstract] [Full Text] [Related]
15. Extreme hypofractionated stereotactic radiotherapy for elderly prostate cancer patients: side effects preliminary analysis of a phase II trial.
Gregucci F; Carbonara R; Surgo A; Ciliberti MP; Curci D; Ciocia A; Branà L; Ludovico GM; Scarcia M; Portoghese F; Caliandro M; Ludovico E; Paulicelli E; Di Guglielmo FC; Bonaparte I; Fiorentino A
Radiol Med; 2023 Apr; 128(4):501-508. PubMed ID: 36952115
[TBL] [Abstract] [Full Text] [Related]
16. Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant prostate cancer.
Omlin A; Cathomas R; von Amsberg G; Reuter C; Feyerabend S; Loidl W; Boegemann M; Lorch A; Heidenreich A; Tsaur I; Larcher-Senn J; Buck SAJ; Mathijssen RHJ; Jaehde U; Gillessen S; Joerger M
Clin Cancer Res; 2023 May; 29(10):1887-1893. PubMed ID: 36917691
[TBL] [Abstract] [Full Text] [Related]
17. Salvage stereotactic reirradiation for intraprostatic cancer recurrence: A large retrospective study.
Allali S; Loap P; Bibault JE; Krepps S; Deforge A; Moreau D; Durdux C; Giraud P
Prostate; 2023 Jun; 83(8):743-750. PubMed ID: 36911892
[TBL] [Abstract] [Full Text] [Related]
18. Prevalence of tumour-infiltrating CD103
Zhou Q; Ou Y; Dai X; Chen X; Wu S; Chen W; Hu M; Yang C; Zhang L; Jiang H
Br J Cancer; 2023 Apr; 128(8):1466-1477. PubMed ID: 36759726
[TBL] [Abstract] [Full Text] [Related]
19. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
[TBL] [Abstract] [Full Text] [Related]
20. Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring.
Lilleby W; Seierstad T; Inderberg EM; Hole KH
Int J Cancer; 2023 May; 152(10):2166-2173. PubMed ID: 36715014
[TBL] [Abstract] [Full Text] [Related]
[Next]
